Masahiro Tohkin Selected Research

Therapeutics

11/2021	BRAF/MEK inhibitor-associated nephrotoxicity in a real-world setting and human kidney cells.
4/2020	Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.
1/2020	Tumor lysis syndrome associated with bortezomib: A post-hoc analysis after signal detection using the US Food and Drug Administration Adverse Event Reporting System.
10/2019	Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma.
1/2017	The Survey of the Compliance Situation to the Antihypertensive Therapy Guideline by Analyzing Japanese National Claims Data.
1/2012	Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
3/2005	Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masahiro Tohkin Research Topics

Disease

6	Neoplasms (Cancer) 11/2021 - 01/2009
6	Stevens-Johnson Syndrome (Lyell's Syndrome) 01/2021 - 11/2008
4	Multiple Myeloma 12/2021 - 10/2019
2	Cicatrix (Scar) 01/2021 - 01/2021
2	Type 2 Diabetes Mellitus (MODY) 01/2020 - 05/2006
2	Weight Gain 01/2019 - 05/2006
1	Pneumonia (Pneumonitis) 12/2021
1	Acute Kidney Injury (Acute Renal Failure) 11/2021
1	Fibrosarcoma 11/2021
1	Melanoma (Melanoma, Malignant) 11/2021
1	Chronic Renal Insufficiency 01/2021
1	Dysuria 01/2021
1	Schizophrenia (Dementia Praecox) 01/2021
1	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/2021
1	Hypersensitivity (Allergy) 01/2021
1	Tumor Lysis Syndrome 01/2020
1	Peripheral Nervous System Diseases (PNS Diseases) 10/2019
1	Hepatitis B 01/2018
1	Infections 01/2018
1	Skin Diseases (Skin Disease) 01/2018
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2017
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2017
1	Heart Failure 01/2017
1	Lactic Acidosis 06/2015
1	Cholestasis 05/2015
1	Alzheimer Disease (Alzheimer's Disease) 01/2015
1	Hypertrophy 01/2015
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2012
1	Stomach Neoplasms (Stomach Cancer) 01/2012
1	Breast Neoplasms (Breast Cancer) 01/2012
1	Hand-Foot Syndrome 01/2012
1	Hypoxia (Hypoxemia) 01/2011
1	Drug-Related Side Effects and Adverse Reactions 01/2010
1	Muscular Diseases (Myopathy) 01/2010
1	Body Weight (Weight, Body) 05/2008

Drug/Important Bio-Agent (IBA)

5	Biomarkers (Surrogate Marker)IBA 12/2021 - 01/2010
5	Pharmaceutical PreparationsIBA 11/2021 - 01/2015
4	Bortezomib (Velcade)FDA Link 12/2021 - 01/2018
4	HLA-B Antigens (HLA-B)IBA 01/2021 - 11/2008
3	Allopurinol (Remid)FDA LinkGeneric 01/2021 - 11/2008
2	Phenytoin (Dilantin)FDA LinkGeneric 01/2021 - 11/2013
2	Carbamazepine (Tegretol)FDA LinkGeneric 01/2021 - 12/2010
2	Lenalidomide (CC 5013)FDA Link 04/2020 - 01/2020
2	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 01/2018
2	SodiumIBA 01/2020 - 01/2018
2	SymportersIBA 01/2020 - 01/2018
2	XenobioticsIBA 01/2015 - 01/2011
1	HLA-DRB1 Chains (HLA DRB1)IBA 12/2021
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 11/2021
1	Phosphotransferases (Kinase)IBA 11/2021
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2021
1	MitogensIBA 11/2021
1	insulin receptor-related receptor (IRR)IBA 01/2021
1	Tadalafil (Cialis)FDA Link 01/2021
1	asenapine FDA Link 01/2021
1	Dexamethasone (Maxidex)FDA LinkGeneric 04/2020
1	Thalidomide (Thalomid)FDA Link 01/2020
1	Proteasome InhibitorsIBA 10/2019
1	Diethylhexyl Phthalate (DEHP)IBA 01/2019
1	p38 Mitogen-Activated Protein KinasesIBA 02/2018
1	Drug CombinationsIBA 01/2018
1	Everolimus FDA Link 01/2018
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2018
1	fludarabineIBA 01/2018
1	Azacitidine (5 Azacytidine)FDA Link 01/2018
1	Antineoplastic Agents (Antineoplastics)IBA 01/2018
1	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2018
1	Docetaxel (Taxotere)FDA Link 01/2018
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2018
1	Rituximab (Mabthera)FDA Link 01/2018
1	Trastuzumab (Herceptin)FDA Link 01/2018
1	Imatinib Mesylate (Gleevec)FDA Link 01/2018
1	taxaneIBA 01/2018
1	Antihypertensive Agents (Antihypertensives)IBA 01/2017
1	DiureticsIBA 01/2017
1	Metformin (Glucophage)FDA LinkGeneric 06/2015
1	Lactic Acid (Lactate)FDA LinkGeneric 06/2015
1	Phenobarbital (Luminal)FDA Link 11/2013
1	Anticonvulsants (Antiepileptic Drugs)IBA 11/2013
1	Zonisamide (Zonegran)FDA LinkGeneric 11/2013
1	Carcinoembryonic AntigenIBA 01/2012
1	ProdrugsIBA 01/2012
1	AntigensIBA 01/2012
1	Tumor Biomarkers (Tumor Markers)IBA 01/2012
1	Fluorouracil (Carac)FDA LinkGeneric 01/2012
1	CarbohydratesIBA 01/2012
1	Capecitabine (Xeloda)FDA Link 01/2012
1	ElementsIBA 01/2011
1	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2011
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2010
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2009
1	Gemcitabine FDA Link 01/2009
1	Cytidine DeaminaseIBA 01/2009
1	Polychlorinated Dibenzodioxins (TCDD)IBA 05/2008
1	glimepiride (Amarel)FDA LinkGeneric 05/2006

Therapy/Procedure

7	Therapeutics 11/2021 - 03/2005
4	Drug Therapy (Chemotherapy) 11/2021 - 01/2010
1	Antineoplastic Combined Chemotherapy Protocols 01/2018
1	Time-to-Treatment 01/2012